To Compare the PK and Safety of Omalizumab(CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy Subjects

2019-07-16 10:38:23 | BioPortfolio


A Phase 1, Randomized, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics and Safety of Three Formulations of Omalizumab (CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy Subjects

Study Design




CT-P39, EU-approved Xolair, CT-P39, EU-approved Xolair, US-licensed Xolair


Not yet recruiting



Results (where available)

View Results


Published on BioPortfolio: 2019-07-16T10:38:23-0400

Clinical Trials [2924 Associated Clinical Trials listed on BioPortfolio]

A Study of Efficacy of New Doses of Xolair to Protect From Allergen Challenge in Groups of Asthma Patients Defined by IgE Levels

This study will demonstrate that patients with standard and high IgE levels can be protected from allergen induced broncho-constriction by Xolair

Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients

This is a pilot randomized, double-blind, placebo controlled study which will be conducted at a single center. All participants will receive oral immunotherapy for their specific food alle...

A Continued Access Protocol to Provide Xolair to Patients With Severe Allergic Asthma

This is a continued access protocol to provide subjects who have completed Genentech, Inc. Study Q2143g, Q2195g, or Q2461g or Novartis Pharmaceuticals Corporation Study CIGE025 0010E1 with...

An Observational Study of the Use and Safety of Xolair During Pregnancy

The Xolair Pregnancy Registry is an observational study established by Genentech to obtain data on pregnancy outcomes in women who are exposed to Xolair. Women exposed to at least one dos...

Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair

The purpose of this study is to study the effects of Xolair using non-invasive techniques from the expired gas of patients with moderate to severe allergic asthma.

PubMed Articles [5761 Associated PubMed Articles listed on BioPortfolio]

Efficacy and safety of omalizumab (Xolair®) for cholinergic urticaria in patients unresponsive to a double dose of antihistamines: a randomized mixed double-blind and open-label placebo-controlled clinical trial.

Cholinergic urticaria (UCOL) is a highly disabling inducible urticaria triggered by an increase in core body temperature.

A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential.

Cannabidiol (CBD) is a highly touted product for many different disorders among the lay press. Numerous CBD products are available, ranging from a US Food and Drug Administration (FDA)-approved produc...

Fluorine-Containing Drugs Approved by the FDA in 2018.

Over the last two decades, fluorine substitution has become one of the essential structural traits in modern pharmaceuticals. Thus, about half of the most successful drugs (blockbuster drugs) contain ...

Community Treatment Orders and Other Forms of Mandatory Outpatient Treatment.

This position paper has been substantially revised by the Canadian Psychiatric Association's Professional Standards and Practice Committee and approved for republication by the CPA's Board of Director...

Added therapeutic value of new drugs approved in Brazil from 2004 to 2016.

This study aimed to assess the level of therapeutic innovation of new drugs approved in Brazil over 13 years and whether they met public health needs. Comparative descriptive analysis of therapeutic v...

Medical and Biotech [MESH] Definitions

Methyl, propyl, butyl, and ethyl esters of p-hydroxybenzoic acid. They have been approved by the FDA as antimicrobial agents for foods and pharmaceuticals. (From Hawley's Condensed Chemical Dictionary, 11th ed, p872)

Professional medical personnel approved to provide care to patients in a hospital.

The practice of prescribing or using a drug outside the scope of the drug's official approved label as designated by a regulatory agency concerning the treatment of a particular disease or condition.

An inflatable device implanted in the stomach as an adjunct to therapy of morbid obesity. Specific types include the silicone Garren-Edwards Gastric Bubble (GEGB), approved by the FDA in 1985, and the Ballobes Balloon.

Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.

More From BioPortfolio on "To Compare the PK and Safety of Omalizumab(CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy Subjects"

Quick Search


Searches Linking to this Trial